Absolutely agree Jeff! But I don't think that was the point of their evaluation. They were looking at ctix with incorrect model. They commented on lack of revenue for instance - that one right there shows their lack of familiarity with R&D level biotech. Then they gave criticism re share and salary structure when compared to most baby biotechs, this company is actually quite strong in that area. So - the point is not success vs failure of r&d level biotech - it is their lack of application of appropriate evaluation model.

They did put their own 'I have no f'in idea what the hell I'm talkin about' nail in the coffin when they said "Leo is just selling stocks and not actually pursuing drug development and trials." That statement shows them incapable of even minimal dd.